3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
14
Gastrointestinal
6
Other hematologic neoplasm
5
Thoracic
4
Myeloid
2
Lymphoid
2
CNS
2
Breast
2
Tumor-Agnostic
1
Plasma cell
1
Other neoplasm
1
Classical hematology
1
Conditions
Breast Neoplasms
1
Breast Neoplasm Female
1
Interventions
Trastuzumab
696
Paclitaxel
679
Cyclophosphamide
634
Docetaxel
554
Capecitabine
468
Letrozole
407
Carboplatin
393
Fulvestrant
379
Doxorubicin
330
Tamoxifen
288
pembrolizumab
272
Anastrozole
252
Epirubicin
249
exemestane
238
pertuzumab
229
Bevacizumab
214
Radiotherapy
213
Gemcitabine
211
Vinorelbine
188
palbociclib
183
Lapatinib
175
130-nm albumin-bound paclitaxel
168
Albumin-Bound Paclitaxel
156
Exercise
147
Magnetic Resonance Spectroscopy
145
eribulin
144
Taxes
134
Fluorouracil
131
Everolimus
118
Cisplatin
118
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Induction Chemotherapy
×
Breast
×
Clear all
NCT01491737
2020-10-28
PERTAIN
Hoffmann-La Roche
Phase 2
Completed
258 enrolled
18 charts
NCT03011060
2017-01-10
NACVCAC
The First Hospital of Jilin University
Phase 3
Unknown
1,588 enrolled